Preparation and Characterization of PLGA Encapsulated Protective Antigen Domain 4 Nanoformulation.
Poly (lactic-co-glycolic acid) (PLGA) based particulate systems have been widely explored for the development of subunit based vaccines owing to its biodegradability, biocompatibility, controlled release of entrapped antigen, targeted delivery potential, and nontoxic degradation product. Here, we describe the preparation of PLGA encapsulated recombinant protective antigen domain 4 (PAD4) nanoformulation (PAD4-NP) and its characterization for antigen content, morphology, and size. We also discuss the method of immunization in mice models to evaluate such PLGA based nanoformulation vaccines.
['Manish|Manish|M|', 'Bhatnagar|Rakesh|R|', 'Singh|Samer|S|']
D000818:Animals D002214:Capsules D004339:Drug Compounding D005260:Female D006867:Hydrolases D007114:Immunization D007074:Immunoglobulin G D019344:Lactic Acid D051379:Mice D053758:Nanoparticles D010316:Particle Size D011100:Polyglycolic Acid D000077182:Polylactic Acid-Polyglycolic Acid Copolymer D000080002:Protein-Arginine Deiminase Type 4 D000076342:Protein-Arginine Deiminases
Vaccine PLGA based nanoparticles Recombinant PAD4 Single dose W/O/W solvent evaporation method